Indonesia's highest Muslim clerical body is expected to issue a halal certification for the experimental COVID-19 vaccine developed by China-based Sinovac Biotech.
The certification would be a significant step in immunisation efforts in the world's most populous Muslim-majority country, should the vaccine be approved for use.
A study by the Indonesian Ulema Council Halal Product Guarantee Agency and Institute for the Assessment of Food, Drugs and Cosmetics has been completed and has been submitted to the council for the making of a fatwa and halal certification, Human Development and Culture Minister Muhadjir Effendy said at a news conference.
Over 1 million doses of the experimental COVID-19 vaccine developed by Sinovac arrived in Indonesia on Sunday evening. The government has no exact schedule for distributing the doses.
Health Minister Terawan Agus Putranto said Monday that the experimental vaccine needs to successfully complete third phase clinical trials before it can be distributed in Indonesia.
The government will provide a vaccine that is proven safe and passes clinical trials under World Health Organisation (WHO) recommendations, Putranto said.
Hermawan Saputra of the Indonesian Public Health Expert Association said the 1.2 million doses are only enough for an initial group of 600,000 people, since each person must receive two doses. It does not really have significant meaning. The government should guarantee that there will be enough to for distribution to the entire country, Saputra said.
Saputra said that if the experimental vaccine passes the third-phase clinical trials, immunisation programmes are expected to begin in the middle of next year.
The government has announced that it plans to use vaccines from several different producers in its effort to vaccinate the world's fourth most populated country. So far, the Sinovac candidate vaccine is the only one to arrive in the country.